Feasibility of gastric endoscopic submucosal dissection with continuous low-dose aspirin for patients receiving dual antiplatelet therapy

Table 7 Comparison of therapeutic outcomes among patients receiving dual antiplatelet therapy in the continuous low-dose aspirin group and the discontinuous low-dose aspirin group

	Continuous LDA (n = 39)	Discontinuous LDA (n = 20)	P value
Pathological findings, n (%)1
Differentiated	39 (100)	19 (95.0)	0.339
Undifferentiated	0 (0)	1 (5.0)
Depth of invasion, n (%)
Mucosa	30 (76.9)	19 (95.0)	0.141
Submucosa	9 (23.1)	1 (5.0)
Specimen size, median (IQR), mm	34 (29.5-40.0)	35 (24.3-36.3)	0.373
Complete resection, n (%)	38 (97.4)	20 (100)	> 0.99
Curative resection, n (%)	33 (84.6)	20 (100)	0.09
Postoperative bleeding, n (%)	9 (23.1)	1 (5.0)	0.141

¹Differentiated, adenoma/well or moderately differentiated adenocarcinoma/papillary adenocarcinoma; undifferentiated, signet-ring cell carcinoma/poorly differentiated adenocarcinoma/mucinous adenocarcinoma. IQR: Interquartile range; LDA: Low-dose aspirin.